Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRECEDE: Tislelizumab + NACT in Laryngeal/Hypopharyngeal Carcinoma
NCT06957938Phase 3Not yet recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- May 2029
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tislelizumab in laryngeal carcinoma and hypopharyngeal carcinoma (HPC) (2 arms), sponsored by Fudan University. Primary endpoint: Laryngectomy-free Survival Rate at 2 years. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
laryngeal carcinomahypopharyngeal carcinoma (HPC)
Beyond the preview
Go deeper on NCT06957938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06957938.